PRESENTATION
Q2 2026 — Presentation
Q2 2026PDF · 33 pages2.3 MB
Second-Quarter 2026 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA August 4, 2026 -- 1 of 33 -- Agenda 2 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Agenda Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session -- 2 of 33 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 33 -- Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer 4 -- 4 of 33 -- 55 1. Non-risk adjusted annual sales by the mid 2030s 2. Clinically derisked defined as first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 3. In collaboration with Kelun Biotech 4. In collaboration with Daiichi Sankyo; FDA PDUFA date October 10, 2026 5. In collaboration with Gilead Accelerating progress toward transformation of portfolio As presented January 2026 Mid 2030s revenue opportunity from current and potential new growth drivers1 >$70B Increasingly clinically derisked 2 Additional innovative pipeline programs remigromig tulisokibart islatravir / lenacapavir5 MK-1406 sacituzumab tirumotecan3 ifinatamab deruxtecan4 Today 2026 2027 2028+ enlicitide -- 5 of 33 -- 66 Accelerating progress toward transformation of portfolio Progress since January 2026 1. Non-risk adjusted annual sales by the mid 2030s 2. Clinically derisked defined as first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 3. In collaboration with Kelun Biotech 4. In collaboration with Daiichi Sankyo; FDA PDUFA date October 10, 2026 5. In collaboration with Gilead Approved 2026 2027 2028+ Mid 2030s revenue opportunity from current and potential new growth drivers1 >$70B Increasingly clinically derisked 2 Additional innovative pipeline programs POSITIVE TOPLINE POSITIVE RESULTS remigromig tulisokibart islatravir / lenacapavir5 POSITIVE TOPLINE UNDER REVIEW MK-1406 sacituzumab tirumotecan3 ifinatamab deruxtecan4 APPROVED -- 6 of 33 -- ¹Weber Shandwick/KCR Research, 2020 / AMO 2019 7 $16.6B Q2 Worldwide Sales Strength in Oncology and Animal Health Increasing contributions from new launches +5% nominal +4% ex-exchange 1. In collaboration Achieved significant pipeline and regulatory progress: • Received several approvals for KEYTRUDA and KEYTRUDA QLEX including one in combination with WELIREG • Presented data at ASCO from multiple novel candidates and broad oncology portfolio • Announced positive topline results for sac-TMT1 in certain patients with advanced or recurrent endometrial cancer Oncology • Announced positive topline results for tulisokibart from induction- only study of Phase 3 ATLAS-UC Immunology • Presented data from innovative HIV portfolio at AIDS 2026 including for islatravir/lenacapavir1 Infectious Diseases • FDA approved LIPFENDRA as first and only oral PCSK9i Cardiometabolic & Respiratory -- 7 of 33 -- 88 Completed strategic acquisition of Terns Pharmaceuticals Adds MK-4208, an investigational next-generation, allosteric TKI for treatment of certain patients with chronic myeloid leukemia Science-driven business development that strengthens and complements hematology pipeline Potential best-in-class profile with opportunity to further improve depth and duration of response in certain patients Multibillion dollar commercial opportunity and growth driver in the next decade, creating shareholder value -- 8 of 33 -- islatravir + ulonivirine NRTI + NNRTI V181 Tetravalent dengue vaccine intismeran autogene4 INT calderasib3 KRAS G12Ci patritumab deruxtecan2 HER3 ADC gocatamig2 DLL3 T-cell engager MK-1045 CD19xCD3 T-cell engager raludotatug deruxtecan2 CDH6 ADC opevesostat CYP11A1i MK-8748 Tie2 agonist/VEGFi 2024-25 2026 2027 2028 2029+ Timing represents approval date for marketed products or announced positive topline results, PDUFA date, or earliest Phase 3 primary completion date according to clinicaltrials.gov for pipeline compounds 1. In collaboration 2. In collaboration with Daiichi Sankyo 3. In collaboration with Taiho Astex 4. In collaboration with Moderna Pipeline candidates with first-in-class potential Successfully executing on strategy to broaden and diversify pipeline 9 islatravir / lenacapavir1 NRTI / capsid inhibitor sacituzumab tirumotecan1 TROP2 ADC ifinatamab deruxtecan1 B7-H3 ADC remigromig Wnt agonist tulisokibart TL1A mAb alimatravir NRTI zilovertamab vedotin ROR1 ADC nemtabrutinib BTKi bomedemstat LSD1i MK-1406 zanamivir-Fc conjugate Cardiometabolic & Respiratory Infectious Disease Oncology Immunology Ophthalmology -- 9 of 33 -- Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer 10 -- 10 of 33 -- 11 Q2 growth across human and animal health with increasing contributions from new products 1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, BRAVECTO QUANTUM and NUMELVI $16.6B+5% nominal +4% ex-exchange WORLDWIDE SALES1 Human Health $14.8B+5% growth +4% ex-exchange Animal Health $1.8B+8% growth +5% ex-exchange 2Q25 2Q26 $1.5B $0.6B Launch product revenue2 OHTUVAYRE sales reported by Verona Pharma -- 11 of 33 -- Oncology: KEYTRUDA continues to benefit patients and drive growth 12 KEYTRUDA family1 sales of $8.4B increased 4% driven by strong uptake in earlier-stage cancers and robust demand from metastatic indications ‒ Growth driven by usage in tumors predominantly affecting women, including those with certain breast and cervical cancers ‒ Increased use of KEYTRUDA in combination with enfortumab vedotin in locally advanced or metastatic urothelial cancer ‒ KEYTRUDA QLEX sales of $463M in 2Q26 following launch in 3Q25; permanent J-code effective April 1st 2Q24 2Q25 2Q26 $7.3B +21%2 $8.4B +4%$8.0B +9% Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~4 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 12 of 33 -- 2Q24 2Q25 2Q26 Oncology: Continued impact for patients across broad portfolio 13 WELIREG sales grew 67% driven by continued higher demand in the U.S. and launch uptake in international markets Lynparza 1 alliance revenue relatively flat compared with prior year Lenvima 2 alliance revenue grew 6%, primarily due to higher demand in the U.S., partially offset by net price Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 2Q24 2Q25 2Q26 $370M +15%$317M +4% $365M -2% 2Q24 2Q25 2Q26 $265M +5% $249M +4% $283M +6% $126M +150% $162M +29% $271M +67% -- 13 of 33 -- Vaccines & Infectious Diseases: Impacting lives globally 2Q24 2Q25 2Q26 2Q24 2Q25 2Q26 Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 2Q26 GARDASIL sales of $1.2B increased 3% driven by higher sales in certain international markets ‒ In the U.S., sales were flat primarily due to lower demand and timing of CDC purchases, largely offset by price CAPVAXIVE 1 sales of $184M increased 40% driven by uptake from ongoing launches in certain international markets and higher demand in the U.S. IDVYNSO2 progress on access and reimbursement following recent launches in U.S. and Japan $184M +40% $2.5B +4% $129M $1.1B -55% $1.2B +3% 14 -- 14 of 33 -- Cardiometabolic & Respiratory: Continuing to drive benefit for patients with successful ongoing launches WINREVAIR sales of $588M driven by continued growth in new patient starts and total prescriptions ‒ In the U.S., ~1,800 new patients prescribed and >34,000 total prescriptions dispensed ‒ Ex-U.S., making progress with ongoing launches OHTUVAYRE 1 sales of $204M reflect continued prescription demand ‒ Benefitted from specialty pharmacy purchase timing, which is expected to unwind in 3Q26 2Q24 2Q25 2Q26 $1.7B +40% 2Q24 2Q25 2Q26 $204M Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma $336M +381% $588M +75% $103M2 $70M 15 -- 15 of 33 -- Animal Health: Solid growth driven by livestock and companion animal 16 Animal Health sales increased 5% to $1.8B ‒ Livestock sales grew 6% driven by higher demand for ruminant and poultry products ‒ Companion Animal sales grew 5% driven by new product launches 2Q24 2Q25 2Q26 $1.5B +6% 1 $1.6B +11% $1.8B +5% Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market -- 16 of 33 -- Q2 2026 non-GAAP financial results summary 1 $ in billions, except LPS / EPS amounts 17 1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q2 2026 non-GAAP results include a charge of $5.7 billion related to the acquisition of Terns Pharmaceuticals, Inc. (Terns). Q2 2025 non-GAAP results include $200 million charge related to the closing of a license agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd. (Hengrui Pharma). 3. Q2 2026 includes a charge of $2.31 per share related to the acquisition of Terns. Q2 2025 includes a charge of $0.07 per share related to the closing of a license agreement with Hengrui Pharma. 4. Q2 2026 GAAP LPS of $(0.54). Q2 2026 Q2 2025 Change Change Ex-FX Sales $16.6 $15.8 +5% +4% Non-GAAP Gross Margin 81.1% 82.2% -1.1 pts -1.5 pts Non-GAAP Operating Expenses2 $12.6 $6.6 91% 90% Non-GAAP Tax Rate 160.3% 15.0% N/M N/A Non-GAAP (Loss) / Earnings Per Share3,4 $(0.13) $2.13 N/M N/M -- 17 of 33 -- 18 Updated 2026 financial outlook 1. Guidance does not assume additional significant potential business development transactions Prior Guidance Updated Guidance Key Assumptions Revenue $65.8B to $67.0B $66.3B to $67.3B • Assumes ~1 percentage point positive impact from FX • Now implies +2% to +4% nominal (+1% to +3% ex-FX) Non-GAAP Gross Margin Rate ~82.0% ~81.0% • Now includes higher inventory reserves Non-GAAP Operating Expenses1 $36.0B to $36.8B $42.0B to $42.7B • Now includes $5.7B charge related to acquisition of Terns Other (Income) / Expense ~$1.3B of expense ~$1.4B of expense • Incorporates financing costs related to acquisition of Terns Tax Rate ~23.5% to 24.5% ~35.0% to 36.0% • Incorporates impact of non-tax deductible charge for Terns Shares Outstanding ~2.48B ~2.48B • Assumes ~$3B of share repurchases Non-GAAP EPS1 $5.04 to $5.16 $2.66 to $2.76 • Incorporates ~$2.31 impact related to upfront charge for acquisition of Terns • Now assumes ~$0.15 positive impact from FX -- 18 of 33 -- Key modeling considerations 19 • Reaching peak penetration in several key indications • Expect headwind from timing of wholesaler purchases in 3Q U.S. KEYTRUDA OHTUVAYRE • Expect 3Q to be impacted by unwind of 2Q specialty pharmacy purchases • Expect investments behind sales force and promotion to drive accelerated growth in 2027 OTHER REVENUE • Expect 2H26 to be significantly higher than 2H25 driven by revenue hedging program and expected milestone receipt in 4Q U.S. BRIDION • Anticipate slower than previously expected sales decline due to lower generic competition -- 19 of 33 -- Remain committed to balanced capital allocation strategy Q2 Spend ($ in billions)1 20 1. Reflects quarter spend 2. Reflects R&D excluding Business Development Augmented our pipeline with value-enhancing business development while investing in our pipeline and business as well as returning cash to shareholders Capital allocation order of priority $3.4 $0.9 $2.1 $6.3 $0.7 After-Tax R&D² CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase -- 20 of 33 -- Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories 21 -- 21 of 33 -- LIPFENDRA the first and only approved oral PCSK9i 22 • First FDA-approved oral PCSK9 inhibitor to reduce LDL-C in adults with hypercholesterolemia, along with diet and exercise • ASCVD remains the leading cause of morbidity and mortality worldwide − Ongoing CORALreef Outcomes trial evaluating effect of LIPFENDRA on cardiovascular morbidity and mortality • Currently under review by EMA and China NMPA • Approval further validates macrocyclic peptide platform • Evaluating potential fixed-dose combinations with rosuvastatin and Lp(a) (MK-7262) LIPFENDRA -- 22 of 33 -- 23 Advancing innovative longer-acting oral treatment options for people living with HIV Islatravir/lenacapavir1 • Presented positive results from Phase 3 ISLEND- 1 and ISLEND-2 studies demonstrating ISL/LEN was effective in adults with virologically suppressed HIV who switched from BIC/FTC/TAF or other oral SoC • Data support potential for ISL/LEN to be first once-weekly oral treatment option Islatravir/ulonivirine • Presented positive Phase 2b results for ISL+ULO demonstrating maintenance of viral suppression in adults with virologically suppressed HIV who switched from BIC/FTC/TAF • Advancing to Phase 3 in new-to-treatment and treatment experienced populations of adults living with HIV 1. In collaboration -- 23 of 33 -- Important updates across infectious disease programs 24 MK-1406 • Phase 3 ANCHOR study completed enrollment in Southern Hemisphere • Plan to enroll second Northern Hemisphere flu season to broaden geographic footprint and support robust global registration strategy • Continue to anticipate potential approval in 2029 CAPVAXIVE • FDA approved expanded indication for children and adolescents aged 2 through 17 years who are at increased risk for pneumococcal disease -- 24 of 33 -- 25 Important progress in immunology clinical development program Tulisokibart • Announced positive topline results of induction-only study in moderately to severely active ulcerative colitis • First anti-TL1A mAb to demonstrate positive results in a Phase 3 trial Broadest TL1A development program Gastroenterology Dermatology Rheumatology ATLAS-UC PCD: Aug 2026 Study 2 ~300 patients 12-week induction-only POSITIVE TOPLINE Study 1 ~720 patients 52-week induction and maintenance Ongoing -- 25 of 33 -- 26 Continuing to advance cancer care with broad, differentiated portfolio and pipeline Positive topline results • KEYNOTE-C93: Announced study evaluating KEYTRUDA monotherapy met primary endpoint of PFS for certain patients with advanced or recurrent endometrial cancer with dMMR tumors versus platinum doublet chemotherapy • TroFuse-005: Announced study evaluating sac-TMT1 met primary endpoints of OS and PFS in patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and anti-PD-1/L1 − First TROP2 ADC to improve OS and PFS compared to chemotherapy in certain patients with advanced or recurrent endometrial cancer − First positive readout from 17 global Phase 3 TroFuse studies Recent approvals • KEYNOTE-9051 : EC approved KEYTRUDA with enfortumab vedotin as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for resectable cis-ineligible MIBC • KEYNOTE-D191 : FDA approved KEYTRUDA and KEYTRUDA QLEX each with sacituzumab govitecan for 1L treatment of PD-L1 positive (CPS ≥ 10) unresectable locally advanced or metastatic TNBC • KEYNOTE-B151 : FDA approved KEYTRUDA and KEYTRUDA QLEX each with enfortumab vedotin-ejfv as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of MIBC • LITESPARK-022: FDA approved KEYTRUDA and KEYTRUDA QLEX each with WELIREG for adjuvant treatment of certain patients with clear cell RCC − 13 KEYTRUDA-based regimens now approved in earlier stage cancer 1. In collaboration -- 26 of 33 -- Significant late-stage pipeline milestones expected over next six months 27 Oncology WELIREG • LITESPARK-011 PDUFA date October 4th I-DXd1 • IDeate-Lung01 PDUFA date October 10th Sac-TMT1 • Presentation of detailed findings from Phase 3 TroFuse-005 trial ESMO Investor Event • Monday, October 26 th at 6 p.m. CET / 1 p.m. ET Cardiometabolic & respiratory WINREVAIR • HYPERION PDUFA date September 21st Immunology Tulisokibart • PCD in August for Phase 3 ATLAS trial in UC • Presentation of detailed findings from Phase 2 study in HS Ophthalmology Remigromig (MK-3000) • PCD in September for Phase 3 BRUNELLO trial in DME 1. In collaboration -- 27 of 33 -- Q&A Robert M. Davis Chairman and Chief Executive Officer Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Caroline Litchfield Executive Vice President and Chief Financial Officer Peter Dannenbaum Senior Vice President, Investor Relations -- 28 of 33 -- 29 Appendix -- 29 of 33 -- Q2 2026 GAAP financial results summary $ in billions, except LPS / EPS amounts 30 Q2 2026 Q2 2025 Change Change Ex-FX Sales $16.6 $15.8 +5% +4% Operating Expenses (SG&A and R&D)1,2 $12.6 $6.7 89% 88% Tax Rate -95.9% 11.4% N/M N/A GAAP (Loss) / Earnings per Share1,2 $(0.54) $1.76 N/M N/M 1. Q2 2026 GAAP results include a charge of $5.7 billion, or $2.31 negative EPS impact, related to the acquisition of Terns 2. 2Q25 GAAP results include $200 million charge, or $0.07 negative EPS impact, related to the closing of a license agreement with Hengrui Pharma -- 30 of 33 -- $13.0 $3.9 $8.3 $26.4 $4.2 $0 $5 $10 $15 $20 $25 $30 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months 31 Capital allocation order of priority 2 1 Executing upon balanced capital allocation strategy 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow Over the past 12 months Committed to the dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026E Dollars per Share +2% +2% +15% +11% +7% +6% +6% +5% +5% +5%Capital investments 2026 to 2030 ~$19B Over 5 years, including more than $14B in the U.S. Well-positioned balance sheet with capacity to fund additional value- enhancing business development opportunities -- 31 of 33 -- Broad and innovative pipeline to address significant unmet medical needs 32 As of August 4, 2026 Phase 3 Oncology MK-1022 (patritumab deruxtecan) 1 Breast MK-1026 (nemtabrutinib) Hematological Malignancies MK-1084 (calderasib) 1 CRC NSCLC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) 1 Esophageal Prostate SCLC (EU) MK-2870 (sacituzumab tirumotecan) 1 Bladder Breast Cervical Endometrial Gastric NSCLC Ovarian MK-1406 Influenza LAGEVRIO (MK-4482) 1,3 COVID-19 (U.S.) MK-8527 (alimatravir) HIV-1 PrEP MK-8591D (islatravir + lenacapavir) 1,2 HIV-1 Infection KEYTRUDA (MK-3475) SCLC MK-3543 (bomedemstat) Myeloproliferative Disorders MK-5684 (opevesostat) Prostate MK-5909 (raludotatug deruxtecan) 1 Ovarian LYNPARZA (MK-7339) 1 NSCLC SCLC V940 (intismeran autogene) 1 Melanoma NSCLC Infectious Diseases MK-1022 (patritumab deruxtecan) 1 Biliary Bladder Cervical Endometrial Esophageal Gastric HCC Melanoma NSCLC Ovarian Pancreatic Prostate MK-1045 Hematological Malignancies MK-1084 (calderasib) 1 Solid Tumors MK-2400 (ifinatamab deruxtecan) 1 Biliary Bladder Breast Cervical Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreatic Solid Tumors MK-2870 (sacituzumab tirumotecan) 1 Biliary Esophageal Neoplasm Malignant Pancreatic Oncology Infectious Diseases MK-8591B (islatravir + ulonivirine) HIV-1 Infection MK-5475 (frespaciguat) PH-COPD MK-5884A (ensifentrine + glycopyrrolate) COPD MK-6024 (efinopegdutide) MASH MK-7262 Atherosclerosis WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic & Respiratory MK-7240 (tulisokibart) Axial Spondyloarthritis Hidradenitis Suppurativa Psoriatic Arthritis Rheumatoid Arthritis Systemic Sclerosis MK-8690 Ulcerative Colitis Immunology MK-3120 Bladder KEYTRUDA (MK-3475) Prostate KEYTRUDA QLEX (MK-3475A) Hematological Malignancies (U.S.) MK-5684 (opevesostat) Breast Endometrial Ovarian MK-5909 (raludotatug deruxtecan) 1 Cervical Endometrial Gastric NSCLC RCC SCLC MK-6070 (gocatamig) 1 SCLC WELIREG (MK-6482) Breast V940 (intismeran autogene) 1 Bladder RCC MK-2214 Alzheimer’s Disease Neuroscience Under regulatory review Oncology MK-2400 (ifinatamab deruxtecan) 1 Previously Treated Extensive-Stage SCLC (U.S.) KEYTRUDA (MK-3475) Cisplatin Eligible MIBC (EU, JPN) Cisplatin Ineligible MIBC (JPN) Newly Diagnosed High-Risk Endometrial (EU) Platinum-Resistant Recurrent Ovarian (JPN) WELIREG (MK-6482) Clear Cell RCC Following Nephrectomy (EU) 5 Previously Treated Advanced RCC (U.S., EU, JPN) 1,6 MK-7240 (tulisokibart) Crohn’s Disease Ulcerative Colitis Immunology MK-3000 (remigromig) 4 Diabetic Macular Edema MK-8748 4 Neovascular Age-Related Macular Degeneration Ophthalmology V181 Dengue Fever Virus Vaccines Phase 3 Phase 2 Infectious Diseases IDVYNSO (MK-8591A) HIV-1 Infection (EU) Cardiometabolic & Respiratory LIPFENDRA (MK-0616) Primary Hypercholesterolemia or Mixed Dyslipidemia (EU) WINREVAIR (MK-7962) Pulmonary arterial hypertension (U.S.) 1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG -- 32 of 33 -- 33 ADC = Antibody-drug conjugate ASCO = American Society of Clinical Oncology ASCVD = Atherosclerotic cardiovascular disease B7-H3 = B7 homolog 3 BIC/FTC/TAF = bictegravir/emtricitabine/tenofovir alafenamide BTKi = Bruton Tyrosine Kinase inhibitor CDH6 = Cadherin-6 COPD = Chronic obstructive pulmonary disease CPS = Combined positive score CRC = Colorectal cancer CYP11A1 = Cytochrome P450 Family 11 Subfamily A Member 1 DLL3 = Delta-like ligand 3 dMMR = Deficient DNA mismatch repair DME = Diabetic macular edema EC = European Commission EMA = European Medicines Agency ESMO = European Society for Medical Oncology HCC = Hepatocellular carcinoma Acronyms OS = Overall survival PCD = Primary completion date PCSK9 = Proprotein convertase subtilisin/Kexin type 9 PD-1/PD-L1 = Programmed cell death protein- 1/Programmed cell death ligand-1 PDUFA = Prescription Drug User Fee Act PFS = Progression free survival RCC = Renal cell carcinoma ROR1 = Receptor tyrosine kinase-like orphan receptor 1 SCLC = Small cell lung cancer SoC = Standard of care TIE2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 TKI = Tyrosine kinase inhibitor TL1A = Tumor Necrosis Factor-like Ligand 1A TNBC = Triple negative breast cancer TROP2 = Trophoblast cell surface antigen-2 UC = Ulcerative colitis ULO = ulonivirine VEGF = Vascular endothelial growth factor HER3 = Human epidermal growth factor receptor 3 HIV-1 = Human Immunodeficiency Virus Type 1 HNSCC = Head and neck squamous cell carcinoma I-DXd = Ifinatamab deruxtecan INT = Individualized neoantigen therapy ISL = islatravir KRAS = Kirsten rat sarcoma viral oncogene homolog LDL-C = Low-density lipoprotein cholesterol LEN = lenacapavir Lp(a) = Lipoprotein(a) LSD1 = Lysine specific demethylase 1 mAb = Monoclonal antibody MASH = Metabolic Dysfunction-Associated Steatohepatitis MIBC = Muscle invasive bladder cancer NSCLC = Non-small cell lung cancer NMPA = National Medical Products Administration NRTI = Nucleoside reverse transcriptase inhibitor NNRTI = Non-nucleoside reverse transcriptase inhibitor -- 33 of 33 --